sorafenib has been researched along with Cancer of Endometrium in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kajitani, T; Katakura, S; Maruyama, T; Masuda, H; Miki, F; Miyazaki, K; Takao, T; Tanaka, M; Tomisato, S; Uchida, H; Uchida, S; Yoshimasa, Y | 1 |
| Chang, TC; Chao, CC; Huang, SL; Sun, NK | 1 |
| Dolcet, X; Dosil, MA; Eritja, N; Felip, I; Gatius, S; Matias-Guiu, X; Mirantes, C; Santacana, M | 1 |
| Bergadà, L; Boyd, J; Chen, BJ; Dolcet, X; Encinas, M; Eritja, N; Gatius, S; Llobet-Navàs, D; Martí, MD; Matias-Guiu, X; Ponce, J; Reventós, J; Ribera, J; Rodríguez-Barrueco, R; Santacana, M; Vidal, A; Villanueva, A; Yeramian, A | 1 |
| Dolcet, X; Domingo, M; Eritja, N; Gonzalez-Tallada, FJ; Llobet, D; Matias-Guiu, X; Pallares, J; Santacana, M; Sorolla, A; Yeramian, A | 1 |
5 other study(ies) available for sorafenib and Cancer of Endometrium
| Article | Year |
|---|---|
Sorafenib targets and inhibits the oncogenic properties of endometrial cancer stem cells via the RAF/ERK pathway.
Topics: Animals; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Endometrial Neoplasms; Female; Humans; Ki-67 Antigen; MAP Kinase Signaling System; Mice; Neoplastic Stem Cells; Sorafenib | 2022 |
Sorafenib induces endometrial carcinoma apoptosis by inhibiting Elk-1-dependent Mcl-1 transcription and inducing Akt/GSK3β-dependent protein degradation.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Endometrial Neoplasms; ets-Domain Protein Elk-1; Female; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; MAP Kinase Signaling System; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Proteolysis; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Sorafenib; Transcription, Genetic | 2013 |
Effects of the multikinase inhibitors Sorafenib and Regorafenib in PTEN deficient neoplasias.
Topics: Animals; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Endometrial Neoplasms; Female; Humans; Male; Niacinamide; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Pyridines; Sorafenib; Thyroid Neoplasms | 2016 |
Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer.
Topics: Animals; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Disease Progression; Endometrial Neoplasms; Endoplasmic Reticulum Stress; Enzyme Activation; Female; Humans; Mice, Nude; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Sorafenib; Xenograft Model Antitumor Assays | 2017 |
The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; CASP8 and FADD-Like Apoptosis Regulating Protein; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Endometrial Neoplasms; fas Receptor; Female; Humans; MAP Kinase Signaling System; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured | 2010 |